AU2004229501B2 - Recombinant IL-9 antibodies and uses thereof - Google Patents

Info

Publication number

AU2004229501B2

AU2004229501B2 AU2004229501A AU2004229501A AU2004229501B2 AU 2004229501 B2 AU2004229501 B2 AU 2004229501B2 AU 2004229501 A AU2004229501 A AU 2004229501A AU 2004229501 A AU2004229501 A AU 2004229501A AU 2004229501 B2 AU2004229501 B2 AU 2004229501B2

Authority

AU

Australia

Prior art keywords

antibody

antibodies

seq

polypeptide

amino acid

Prior art date

2003-04-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 108010002335 Interleukin-9 Proteins 0.000 title claims abstract description 345
• 102000000585 Interleukin-9 Human genes 0.000 claims abstract description 342
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 276
• 201000010099 disease Diseases 0.000 claims abstract description 154
• 208000035475 disorder Diseases 0.000 claims abstract description 120
• 230000000694 effects Effects 0.000 claims abstract description 116
• 230000014509 gene expression Effects 0.000 claims abstract description 108
• 230000001594 aberrant effect Effects 0.000 claims abstract description 83
• 238000000034 method Methods 0.000 claims abstract description 57
• 238000004519 manufacturing process Methods 0.000 claims abstract description 16
• 239000000203 mixture Substances 0.000 claims abstract description 14
• 239000003795 chemical substances by application Substances 0.000 claims description 165
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 148
• 239000003814 drug Substances 0.000 claims description 76
• 230000000069 prophylactic effect Effects 0.000 claims description 65
• 241000282414 Homo sapiens Species 0.000 claims description 60
• 229940124597 therapeutic agent Drugs 0.000 claims description 57
• 239000005557 antagonist Substances 0.000 claims description 31
• 208000006673 asthma Diseases 0.000 claims description 20
• 206010020751 Hypersensitivity Diseases 0.000 claims description 19
• 239000002253 acid Substances 0.000 claims description 18
• 102100040247 Tumor necrosis factor Human genes 0.000 claims description 14
• 239000004037 angiogenesis inhibitor Substances 0.000 claims description 14
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 13
• 230000007815 allergy Effects 0.000 claims description 10
• 208000026935 allergic disease Diseases 0.000 claims description 8
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 8
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 8
• 108010044426 integrins Proteins 0.000 claims description 8
• 102000006495 integrins Human genes 0.000 claims description 8
• 238000000338 in vitro Methods 0.000 claims description 7
• 230000002757 inflammatory effect Effects 0.000 claims description 4
• 239000005022 packaging material Substances 0.000 claims description 3
• 239000012472 biological sample Substances 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 239000008177 pharmaceutical agent Substances 0.000 claims 1
• 208000015181 infectious disease Diseases 0.000 abstract description 73
• 208000023275 Autoimmune disease Diseases 0.000 abstract description 58
• 208000027866 inflammatory disease Diseases 0.000 abstract description 55
• 230000002062 proliferating effect Effects 0.000 abstract description 45
• 108010038414 Interleukin-9 Receptors Proteins 0.000 abstract description 30
• 208000037765 diseases and disorders Diseases 0.000 abstract description 3
• 238000012544 monitoring process Methods 0.000 abstract description 3
• 102000010682 Interleukin-9 Receptors Human genes 0.000 abstract 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 182
• 102000004196 processed proteins & peptides Human genes 0.000 description 156
• 229920001184 polypeptide Polymers 0.000 description 112
• 108090000623 proteins and genes Proteins 0.000 description 112
• 239000012634 fragment Substances 0.000 description 109
• 235000018102 proteins Nutrition 0.000 description 98
• 102000004169 proteins and genes Human genes 0.000 description 98
• 238000002560 therapeutic procedure Methods 0.000 description 97
• 102100026244 Interleukin-9 receptor Human genes 0.000 description 79
• 210000004027 cell Anatomy 0.000 description 78
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 75
• 210000003630 histaminocyte Anatomy 0.000 description 73
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 71
• 239000002953 phosphate buffered saline Substances 0.000 description 71
• 125000000539 amino acid group Chemical group 0.000 description 67
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 62
• 230000002519 immonomodulatory effect Effects 0.000 description 61
• 206010057190 Respiratory tract infections Diseases 0.000 description 60
• 102000036639 antigens Human genes 0.000 description 57
• 239000000427 antigen Substances 0.000 description 56
• 108091007433 antigens Proteins 0.000 description 56
• 230000027455 binding Effects 0.000 description 56
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 53
• 108040006862 interleukin-9 receptor activity proteins Proteins 0.000 description 51
• 150000007523 nucleic acids Chemical group 0.000 description 50
• 208000024891 symptom Diseases 0.000 description 50
• 125000003729 nucleotide group Chemical group 0.000 description 48
• 238000000099 in vitro assay Methods 0.000 description 47
• 238000005462 in vivo assay Methods 0.000 description 47
• 239000002773 nucleotide Substances 0.000 description 46
• 102000039446 nucleic acids Human genes 0.000 description 43
• 108020004707 nucleic acids Proteins 0.000 description 43
• 238000011282 treatment Methods 0.000 description 42
• 235000001014 amino acid Nutrition 0.000 description 40
• 238000003556 assay Methods 0.000 description 36
• 102000004127 Cytokines Human genes 0.000 description 35
• 108090000695 Cytokines Proteins 0.000 description 35
• 210000001744 T-lymphocyte Anatomy 0.000 description 34
• 230000008595 infiltration Effects 0.000 description 33
• 238000001764 infiltration Methods 0.000 description 33
• -1 vapors Substances 0.000 description 32
• 150000001413 amino acids Chemical class 0.000 description 28
• 230000006870 function Effects 0.000 description 27
• 230000001225 therapeutic effect Effects 0.000 description 27
• 229940024606 amino acid Drugs 0.000 description 26
• 230000002265 prevention Effects 0.000 description 26
• 241000700605 Viruses Species 0.000 description 25
• 108020001507 fusion proteins Proteins 0.000 description 25
• 102000037865 fusion proteins Human genes 0.000 description 25
• 241001465754 Metazoa Species 0.000 description 23
• 238000006467 substitution reaction Methods 0.000 description 23
• 102000003675 cytokine receptors Human genes 0.000 description 22
• 108010057085 cytokine receptors Proteins 0.000 description 22
• 210000002540 macrophage Anatomy 0.000 description 22
• 210000001519 tissue Anatomy 0.000 description 22
• 238000002965 ELISA Methods 0.000 description 21
• 230000035755 proliferation Effects 0.000 description 21
• 102000005962 receptors Human genes 0.000 description 21
• 108020003175 receptors Proteins 0.000 description 21
• 108091028043 Nucleic acid sequence Proteins 0.000 description 20
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 20
• 210000002966 serum Anatomy 0.000 description 19
• 201000008827 tuberculosis Diseases 0.000 description 19
• 210000003719 b-lymphocyte Anatomy 0.000 description 18
• 210000004072 lung Anatomy 0.000 description 18
• 230000004913 activation Effects 0.000 description 17
• 229940079593 drug Drugs 0.000 description 17
• 230000028993 immune response Effects 0.000 description 17
• 230000003993 interaction Effects 0.000 description 17
• 238000007726 management method Methods 0.000 description 17
• 108091008874 T cell receptors Proteins 0.000 description 16
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 16
• 230000000241 respiratory effect Effects 0.000 description 16
• 108090000978 Interleukin-4 Proteins 0.000 description 15
• 102000004388 Interleukin-4 Human genes 0.000 description 15
• 108010058846 Ovalbumin Proteins 0.000 description 15
• 206010035664 Pneumonia Diseases 0.000 description 15
• 239000003242 anti bacterial agent Substances 0.000 description 15
• 238000001727 in vivo Methods 0.000 description 15
• 230000009467 reduction Effects 0.000 description 15
• 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 14
• 241000894006 Bacteria Species 0.000 description 14
• 230000000890 antigenic effect Effects 0.000 description 14
• 238000009396 hybridization Methods 0.000 description 14
• 230000001965 increasing effect Effects 0.000 description 14
• 229940092253 ovalbumin Drugs 0.000 description 14
• 239000000126 substance Substances 0.000 description 14
• 241000342334 Human metapneumovirus Species 0.000 description 13
• 210000002345 respiratory system Anatomy 0.000 description 13
• 101001055216 Homo sapiens Interleukin-9 Proteins 0.000 description 12
• 206010061218 Inflammation Diseases 0.000 description 12
• 230000001772 anti-angiogenic effect Effects 0.000 description 12
• 210000003979 eosinophil Anatomy 0.000 description 12
• 102000052627 human IL9 Human genes 0.000 description 12
• 230000004054 inflammatory process Effects 0.000 description 12
• 210000000056 organ Anatomy 0.000 description 12
• 239000000047 product Substances 0.000 description 12
• 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 11
• 230000001413 cellular effect Effects 0.000 description 11
• 238000011161 development Methods 0.000 description 11
• 230000018109 developmental process Effects 0.000 description 11
• 238000003018 immunoassay Methods 0.000 description 11
• 210000004969 inflammatory cell Anatomy 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 210000000440 neutrophil Anatomy 0.000 description 11
• 231100000164 trypan blue assay Toxicity 0.000 description 11
• 229960005486 vaccine Drugs 0.000 description 11
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 10
• 239000003246 corticosteroid Substances 0.000 description 10
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
• 230000003472 neutralizing effect Effects 0.000 description 10
• 150000003384 small molecules Chemical class 0.000 description 10
• 229940104230 thymidine Drugs 0.000 description 10
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 9
• 101001055219 Homo sapiens Interleukin-9 receptor Proteins 0.000 description 9
• 102000003814 Interleukin-10 Human genes 0.000 description 9
• 108090000174 Interleukin-10 Proteins 0.000 description 9
• 208000002606 Paramyxoviridae Infections Diseases 0.000 description 9
• 102000035195 Peptidases Human genes 0.000 description 9
• 108091005804 Peptidases Proteins 0.000 description 9
• 229940088710 antibiotic agent Drugs 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 201000003984 candidiasis Diseases 0.000 description 9
• 210000000987 immune system Anatomy 0.000 description 9
• 230000026731 phosphorylation Effects 0.000 description 9
• 238000006366 phosphorylation reaction Methods 0.000 description 9
• 230000003612 virological effect Effects 0.000 description 9
• 241001519465 Avian metapneumovirus Species 0.000 description 8
• 241000233866 Fungi Species 0.000 description 8
• 241000124008 Mammalia Species 0.000 description 8
• 241001529936 Murinae Species 0.000 description 8
• 239000004365 Protease Substances 0.000 description 8
• 239000002671 adjuvant Substances 0.000 description 8
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 8
• 230000001419 dependent effect Effects 0.000 description 8
• 238000003745 diagnosis Methods 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 239000002243 precursor Substances 0.000 description 8
• 235000019419 proteases Nutrition 0.000 description 8
• 230000002685 pulmonary effect Effects 0.000 description 8
• 229940075993 receptor modulator Drugs 0.000 description 8
• 241000894007 species Species 0.000 description 8
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 7
• 241000271566 Aves Species 0.000 description 7
• 108010029697 CD40 Ligand Proteins 0.000 description 7
• 102100032937 CD40 ligand Human genes 0.000 description 7
• 108020004414 DNA Proteins 0.000 description 7
• 108060003951 Immunoglobulin Proteins 0.000 description 7
• 108010065805 Interleukin-12 Proteins 0.000 description 7
• 102000013462 Interleukin-12 Human genes 0.000 description 7
• 102000003812 Interleukin-15 Human genes 0.000 description 7
• 108090000172 Interleukin-15 Proteins 0.000 description 7
• 102000000588 Interleukin-2 Human genes 0.000 description 7
• 108010002350 Interleukin-2 Proteins 0.000 description 7
• 206010028980 Neoplasm Diseases 0.000 description 7
• 108090001074 Nucleocapsid Proteins Proteins 0.000 description 7
• 229960003942 amphotericin b Drugs 0.000 description 7
• 230000004071 biological effect Effects 0.000 description 7
• 230000004663 cell proliferation Effects 0.000 description 7
• 229960001334 corticosteroids Drugs 0.000 description 7
• 229940127089 cytotoxic agent Drugs 0.000 description 7
• 231100000599 cytotoxic agent Toxicity 0.000 description 7
• 230000006378 damage Effects 0.000 description 7
• 230000004069 differentiation Effects 0.000 description 7
• TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 7
• 102000018358 immunoglobulin Human genes 0.000 description 7
• 229940079322 interferon Drugs 0.000 description 7
• 150000002617 leukotrienes Chemical class 0.000 description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
• 210000000130 stem cell Anatomy 0.000 description 7
• 102400000068 Angiostatin Human genes 0.000 description 6
• 108010079709 Angiostatins Proteins 0.000 description 6
• 241000222122 Candida albicans Species 0.000 description 6
• 201000007336 Cryptococcosis Diseases 0.000 description 6
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
• 102000000646 Interleukin-3 Human genes 0.000 description 6
• 108010002386 Interleukin-3 Proteins 0.000 description 6
• 108010002616 Interleukin-5 Proteins 0.000 description 6
• 102100039897 Interleukin-5 Human genes 0.000 description 6
• 206010037660 Pyrexia Diseases 0.000 description 6
• 210000004241 Th2 cell Anatomy 0.000 description 6
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
• 230000000692 anti-sense effect Effects 0.000 description 6
• 239000004019 antithrombin Substances 0.000 description 6
• 239000003443 antiviral agent Substances 0.000 description 6
• 201000011510 cancer Diseases 0.000 description 6
• 238000001516 cell proliferation assay Methods 0.000 description 6
• XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 6
• 229960004413 flucytosine Drugs 0.000 description 6
• 239000003018 immunosuppressive agent Substances 0.000 description 6
• 230000028709 inflammatory response Effects 0.000 description 6
• 229940118526 interleukin-9 Drugs 0.000 description 6
• 238000001990 intravenous administration Methods 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 230000019491 signal transduction Effects 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• 208000030507 AIDS Diseases 0.000 description 5
• 241000228212 Aspergillus Species 0.000 description 5
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 5
• 206010007134 Candida infections Diseases 0.000 description 5
• 241000557626 Corvus corax Species 0.000 description 5
• 206010011224 Cough Diseases 0.000 description 5
• 241000221204 Cryptococcus neoformans Species 0.000 description 5
• 108010092160 Dactinomycin Proteins 0.000 description 5
• 102000003886 Glycoproteins Human genes 0.000 description 5
• 108090000288 Glycoproteins Proteins 0.000 description 5
• 241000711920 Human orthopneumovirus Species 0.000 description 5
• 108010050904 Interferons Proteins 0.000 description 5
• 102000014150 Interferons Human genes 0.000 description 5
• 102000003816 Interleukin-13 Human genes 0.000 description 5
• 108090000176 Interleukin-13 Proteins 0.000 description 5
• 108010065637 Interleukin-23 Proteins 0.000 description 5
• 102000013264 Interleukin-23 Human genes 0.000 description 5
• 108090001005 Interleukin-6 Proteins 0.000 description 5
• 102000004889 Interleukin-6 Human genes 0.000 description 5
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
• 241000286209 Phasianidae Species 0.000 description 5
• 239000002202 Polyethylene glycol Substances 0.000 description 5
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 5
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 5
• 206010042938 Systemic candida Diseases 0.000 description 5
• 229940121375 antifungal agent Drugs 0.000 description 5
• 239000003429 antifungal agent Substances 0.000 description 5
• 239000002246 antineoplastic agent Substances 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 230000020411 cell activation Effects 0.000 description 5
• 239000012707 chemical precursor Substances 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 238000011461 current therapy Methods 0.000 description 5
• 239000002254 cytotoxic agent Substances 0.000 description 5
• 230000034994 death Effects 0.000 description 5
• 231100000517 death Toxicity 0.000 description 5
• 230000004927 fusion Effects 0.000 description 5
• 230000000521 hyperimmunizing effect Effects 0.000 description 5
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 5
• 230000002163 immunogen Effects 0.000 description 5
• 229940125721 immunosuppressive agent Drugs 0.000 description 5
• 239000003112 inhibitor Substances 0.000 description 5
• 208000014674 injury Diseases 0.000 description 5
• 150000002484 inorganic compounds Chemical class 0.000 description 5
• 229910010272 inorganic material Inorganic materials 0.000 description 5
• 230000003902 lesion Effects 0.000 description 5
• 210000004698 lymphocyte Anatomy 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 229960000485 methotrexate Drugs 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 150000002894 organic compounds Chemical class 0.000 description 5
• 230000000750 progressive effect Effects 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 208000023504 respiratory system disease Diseases 0.000 description 5
• 239000000523 sample Substances 0.000 description 5
• 229950003804 siplizumab Drugs 0.000 description 5
• 201000002909 Aspergillosis Diseases 0.000 description 4
• 208000036641 Aspergillus infections Diseases 0.000 description 4
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical class CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 108010079505 Endostatins Proteins 0.000 description 4
• 102000006395 Globulins Human genes 0.000 description 4
• 108010044091 Globulins Proteins 0.000 description 4
• 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 4
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
• 241000351643 Metapneumovirus Species 0.000 description 4
• 102000013566 Plasminogen Human genes 0.000 description 4
• 108010051456 Plasminogen Proteins 0.000 description 4
• 102000004211 Platelet factor 4 Human genes 0.000 description 4
• 108090000778 Platelet factor 4 Proteins 0.000 description 4
• 241000711902 Pneumovirus Species 0.000 description 4
• 108091030071 RNAI Proteins 0.000 description 4
• 206010070834 Sensitisation Diseases 0.000 description 4
• 241000144282 Sigmodon Species 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
• 108090000190 Thrombin Proteins 0.000 description 4
• VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• 230000021736 acetylation Effects 0.000 description 4
• 238000006640 acetylation reaction Methods 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 230000002411 adverse Effects 0.000 description 4
• 239000000443 aerosol Substances 0.000 description 4
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 4
• 229910052782 aluminium Inorganic materials 0.000 description 4
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
• VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 4
• 230000000844 anti-bacterial effect Effects 0.000 description 4
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 210000003651 basophil Anatomy 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 238000002648 combination therapy Methods 0.000 description 4
• 150000001875 compounds Chemical class 0.000 description 4
• 230000021615 conjugation Effects 0.000 description 4
• SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 230000007613 environmental effect Effects 0.000 description 4
• 210000002919 epithelial cell Anatomy 0.000 description 4
• 210000000981 epithelium Anatomy 0.000 description 4
• 230000009368 gene silencing by RNA Effects 0.000 description 4
• 230000009931 harmful effect Effects 0.000 description 4
• 210000002443 helper t lymphocyte Anatomy 0.000 description 4
• 239000012678 infectious agent Substances 0.000 description 4
• 206010022000 influenza Diseases 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 208000030500 lower respiratory tract disease Diseases 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 238000011275 oncology therapy Methods 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 229910052760 oxygen Inorganic materials 0.000 description 4
• 229960000402 palivizumab Drugs 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 230000002797 proteolythic effect Effects 0.000 description 4
• 230000006337 proteolytic cleavage Effects 0.000 description 4
• 238000003127 radioimmunoassay Methods 0.000 description 4
• 208000020029 respiratory tract infectious disease Diseases 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• 229960002052 salbutamol Drugs 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 230000008313 sensitization Effects 0.000 description 4
• 230000001235 sensitizing effect Effects 0.000 description 4
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 150000003431 steroids Chemical class 0.000 description 4
• 230000008961 swelling Effects 0.000 description 4
• 230000002195 synergetic effect Effects 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 229960004072 thrombin Drugs 0.000 description 4
• MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
• 102000004411 Antithrombin III Human genes 0.000 description 3
• 108090000935 Antithrombin III Proteins 0.000 description 3
• 206010003487 Aspergilloma Diseases 0.000 description 3
• 108700031361 Brachyury Proteins 0.000 description 3
• 206010006448 Bronchiolitis Diseases 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
• 108090000227 Chymases Proteins 0.000 description 3
• 102000003858 Chymases Human genes 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 241000282326 Felis catus Species 0.000 description 3
• 102100037362 Fibronectin Human genes 0.000 description 3
• 108010067306 Fibronectins Proteins 0.000 description 3
• 241000287828 Gallus gallus Species 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
• 101710154606 Hemagglutinin Proteins 0.000 description 3
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
• 101500025915 Homo sapiens Angiostatin Proteins 0.000 description 3
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• 206010061598 Immunodeficiency Diseases 0.000 description 3
• 108010002586 Interleukin-7 Proteins 0.000 description 3
• 108010063954 Mucins Proteins 0.000 description 3
• 102000015728 Mucins Human genes 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• 208000010359 Newcastle Disease Diseases 0.000 description 3
• 244000061176 Nicotiana tabacum Species 0.000 description 3
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
• 229930182555 Penicillin Natural products 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• 241000711904 Pneumoviridae Species 0.000 description 3
• 241000288906 Primates Species 0.000 description 3
• 206010036790 Productive cough Diseases 0.000 description 3
• 102100024819 Prolactin Human genes 0.000 description 3
• 108010057464 Prolactin Proteins 0.000 description 3
• 101710176177 Protein A56 Proteins 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 208000001647 Renal Insufficiency Diseases 0.000 description 3
• 208000037656 Respiratory Sounds Diseases 0.000 description 3
• 230000006052 T cell proliferation Effects 0.000 description 3
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
• 102000001400 Tryptase Human genes 0.000 description 3
• 108060005989 Tryptase Proteins 0.000 description 3
• 206010046306 Upper respiratory tract infection Diseases 0.000 description 3
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
• 229960001138 acetylsalicylic acid Drugs 0.000 description 3
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
• 230000000843 anti-fungal effect Effects 0.000 description 3
• 229940125715 antihistaminic agent Drugs 0.000 description 3
• 239000000739 antihistaminic agent Substances 0.000 description 3
• 229960005348 antithrombin iii Drugs 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 210000000621 bronchi Anatomy 0.000 description 3
• 208000037976 chronic inflammation Diseases 0.000 description 3
• 230000006020 chronic inflammation Effects 0.000 description 3
• 230000015271 coagulation Effects 0.000 description 3
• 238000005345 coagulation Methods 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 230000001268 conjugating effect Effects 0.000 description 3
• 229960000640 dactinomycin Drugs 0.000 description 3
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 3
• 238000001212 derivatisation Methods 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 238000010494 dissociation reaction Methods 0.000 description 3
• 230000005593 dissociations Effects 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 229960004884 fluconazole Drugs 0.000 description 3
• RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
• 230000002538 fungal effect Effects 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 229960002897 heparin Drugs 0.000 description 3
• 229920000669 heparin Polymers 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 239000002085 irritant Substances 0.000 description 3
• 231100000021 irritant Toxicity 0.000 description 3
• 201000006370 kidney failure Diseases 0.000 description 3
• 239000003199 leukotriene receptor blocking agent Substances 0.000 description 3
• 125000005647 linker group Chemical group 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 229910021645 metal ion Inorganic materials 0.000 description 3
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 229940049954 penicillin Drugs 0.000 description 3
• 230000010412 perfusion Effects 0.000 description 3
• 229960003171 plicamycin Drugs 0.000 description 3
• 108091033319 polynucleotide Proteins 0.000 description 3
• 102000040430 polynucleotide Human genes 0.000 description 3
• 239000002157 polynucleotide Substances 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 229940097325 prolactin Drugs 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 238000012163 sequencing technique Methods 0.000 description 3
• 239000000779 smoke Substances 0.000 description 3
• 208000024794 sputum Diseases 0.000 description 3
• 210000003802 sputum Anatomy 0.000 description 3
• 230000000451 tissue damage Effects 0.000 description 3
• 231100000827 tissue damage Toxicity 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 230000001052 transient effect Effects 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
• VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
• VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
• MSLYUFAHRVRLKU-UHFFFAOYSA-N 7,10,15-trihydroxypentacyclo[10.7.1.02,11.03,8.016,20]icosa-1,3(8),4,6,10,12(20),13,15,18-nonaene-9,17-dione Chemical compound Oc1ccc2c3c(O)c(=O)c4c(O)cccc4c3c3ccc(=O)c1c23 MSLYUFAHRVRLKU-UHFFFAOYSA-N 0.000 description 2
• 241000238876 Acari Species 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
• 241001225321 Aspergillus fumigatus Species 0.000 description 2
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
• 241000711404 Avian avulavirus 1 Species 0.000 description 2
• 230000003844 B-cell-activation Effects 0.000 description 2
• 241000304886 Bacilli Species 0.000 description 2
• 108010006654 Bleomycin Proteins 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 241000711895 Bovine orthopneumovirus Species 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 229930186147 Cephalosporin Natural products 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 208000003322 Coinfection Diseases 0.000 description 2
• 108010001463 Collagen Type XVIII Proteins 0.000 description 2
• 102000047200 Collagen Type XVIII Human genes 0.000 description 2
• 208000002330 Congenital Heart Defects Diseases 0.000 description 2
• 206010011416 Croup infectious Diseases 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• 201000003883 Cystic fibrosis Diseases 0.000 description 2
• 101710112752 Cytotoxin Proteins 0.000 description 2
• 208000019505 Deglutition disease Diseases 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• 108700021041 Disintegrin Proteins 0.000 description 2
• 206010013975 Dyspnoeas Diseases 0.000 description 2
• 238000008157 ELISA kit Methods 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• 206010015150 Erythema Diseases 0.000 description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
• 108010080865 Factor XII Proteins 0.000 description 2
• 102000000429 Factor XII Human genes 0.000 description 2
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• 108091006027 G proteins Proteins 0.000 description 2
• 108091000058 GTP-Binding Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 108060003393 Granulin Proteins 0.000 description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
• 108700004031 HN Proteins 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 2
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 102000000704 Interleukin-7 Human genes 0.000 description 2
• ZZWAFVPZTZSAEM-RIGQTMPJSA-N KT 5926 Chemical compound C12=CC=CC=C2C2=C(CNC3=O)C3=C3C4=CC(OCCC)=CC=C4N4C3=C2N1[C@]1(C)[C@@](O)(C(=O)OC)C[C@H]4O1 ZZWAFVPZTZSAEM-RIGQTMPJSA-N 0.000 description 2
• 102100035792 Kininogen-1 Human genes 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 2
• 108010063045 Lactoferrin Proteins 0.000 description 2
• 102000010445 Lactoferrin Human genes 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
• UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 2
• 241000712045 Morbillivirus Species 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 208000031888 Mycoses Diseases 0.000 description 2
• KKMPSGJPCCJYRV-UHFFFAOYSA-N Nitidine Chemical compound C1=C2C3=[N+](C)C=C4C=C(OC)C(OC)=CC4=C3C=CC2=CC2=C1OCO2 KKMPSGJPCCJYRV-UHFFFAOYSA-N 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 241000711504 Paramyxoviridae Species 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 108010089430 Phosphoproteins Proteins 0.000 description 2
• 102000007982 Phosphoproteins Human genes 0.000 description 2
• 108090000113 Plasma Kallikrein Proteins 0.000 description 2
• 206010067565 Pneumonia cryptococcal Diseases 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 102000003743 Relaxin Human genes 0.000 description 2
• 108090000103 Relaxin Proteins 0.000 description 2
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 2
• 241000725643 Respiratory syncytial virus Species 0.000 description 2
• 206010062106 Respiratory tract infection viral Diseases 0.000 description 2
• 206010039101 Rhinorrhoea Diseases 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 102000005686 Serum Globulins Human genes 0.000 description 2
• 108010045362 Serum Globulins Proteins 0.000 description 2
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
• 241000193998 Streptococcus pneumoniae Species 0.000 description 2
• 208000018359 Systemic autoimmune disease Diseases 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
• 108091008605 VEGF receptors Proteins 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 206010047924 Wheezing Diseases 0.000 description 2
• YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 229930183665 actinomycin Natural products 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 230000010085 airway hyperresponsiveness Effects 0.000 description 2
• 239000013566 allergen Substances 0.000 description 2
• 230000000172 allergic effect Effects 0.000 description 2
• 230000009435 amidation Effects 0.000 description 2
• 238000007112 amidation reaction Methods 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 230000003092 anti-cytokine Effects 0.000 description 2
• 230000000840 anti-viral effect Effects 0.000 description 2
• 230000005875 antibody response Effects 0.000 description 2
• 229940091771 aspergillus fumigatus Drugs 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 229960005370 atorvastatin Drugs 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 229960002170 azathioprine Drugs 0.000 description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 230000005540 biological transmission Effects 0.000 description 2
• 229960001561 bleomycin Drugs 0.000 description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 230000005983 bone marrow dysfunction Effects 0.000 description 2
• 229940098773 bovine serum albumin Drugs 0.000 description 2
• 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 2
• LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 2
• 230000004856 capillary permeability Effects 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 210000002421 cell wall Anatomy 0.000 description 2
• 229940124587 cephalosporin Drugs 0.000 description 2
• 150000001780 cephalosporins Chemical class 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 210000000038 chest Anatomy 0.000 description 2
• 235000013330 chicken meat Nutrition 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• JKNIRLKHOOMGOJ-UHFFFAOYSA-N cladochrome D Natural products COC1=C(CC(C)OC(=O)Oc2ccc(O)cc2)c3c4C(=C(OC)C(=O)c5c(O)cc(OC)c(c45)c6c(OC)cc(O)c(C1=O)c36)CC(C)OC(=O)c7ccc(O)cc7 JKNIRLKHOOMGOJ-UHFFFAOYSA-N 0.000 description 2
• SRJYZPCBWDVSGO-UHFFFAOYSA-N cladochrome E Natural products COC1=CC(O)=C(C(C(OC)=C(CC(C)OC(=O)OC=2C=CC(O)=CC=2)C2=3)=O)C2=C1C1=C(OC)C=C(O)C(C(C=2OC)=O)=C1C=3C=2CC(C)OC(=O)C1=CC=CC=C1 SRJYZPCBWDVSGO-UHFFFAOYSA-N 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000012411 cloning technique Methods 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 201000010549 croup Diseases 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 239000002619 cytotoxin Substances 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 229960001259 diclofenac Drugs 0.000 description 2
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 239000000428 dust Substances 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 210000003238 esophagus Anatomy 0.000 description 2
• AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 230000022244 formylation Effects 0.000 description 2
• 238000006170 formylation reaction Methods 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 229940045109 genistein Drugs 0.000 description 2
• 235000006539 genistein Nutrition 0.000 description 2
• ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
• 239000003862 glucocorticoid Substances 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 239000000185 hemagglutinin Substances 0.000 description 2
• 229960001340 histamine Drugs 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 229960004171 hydroxychloroquine Drugs 0.000 description 2
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
• 229960001680 ibuprofen Drugs 0.000 description 2
• 229960002411 imatinib Drugs 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 229940127121 immunoconjugate Drugs 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000004941 influx Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• 229960004130 itraconazole Drugs 0.000 description 2
• CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
• 229940078795 lactoferrin Drugs 0.000 description 2
• 235000021242 lactoferrin Nutrition 0.000 description 2
• 150000002605 large molecules Chemical class 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 230000002101 lytic effect Effects 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 229960004584 methylprednisolone Drugs 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 229960005127 montelukast Drugs 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 208000010753 nasal discharge Diseases 0.000 description 2
• 210000001331 nose Anatomy 0.000 description 2
• 230000000474 nursing effect Effects 0.000 description 2
• 229960000470 omalizumab Drugs 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000006320 pegylation Effects 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 239000000816 peptidomimetic Substances 0.000 description 2
• 210000003800 pharynx Anatomy 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• CGFVUVWMYIHGHS-UHFFFAOYSA-N saintopin Chemical compound C1=C(O)C=C2C=C(C(=O)C=3C(=C(O)C=C(C=3)O)C3=O)C3=C(O)C2=C1O CGFVUVWMYIHGHS-UHFFFAOYSA-N 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 238000011125 single therapy Methods 0.000 description 2
• 238000009097 single-agent therapy Methods 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• 229910001415 sodium ion Inorganic materials 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 238000009120 supportive therapy Methods 0.000 description 2
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
• 229940036185 synagis Drugs 0.000 description 2
• 229940037128 systemic glucocorticoids Drugs 0.000 description 2
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
• 229960000195 terbutaline Drugs 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 229960000303 topotecan Drugs 0.000 description 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
• 229960005267 tositumomab Drugs 0.000 description 2
• 210000003437 trachea Anatomy 0.000 description 2
• 230000001960 triggered effect Effects 0.000 description 2
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 241000712461 unidentified influenza virus Species 0.000 description 2
• 208000011479 upper respiratory tract disease Diseases 0.000 description 2
• 210000001215 vagina Anatomy 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 229940124549 vasodilator Drugs 0.000 description 2
• 239000003071 vasodilator agent Substances 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 210000002845 virion Anatomy 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 2
• QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 2
• 229960004764 zafirlukast Drugs 0.000 description 2
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
• FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• PDYBUYVOPAJLKP-UHFFFAOYSA-M 2,3,10,11-tetramethoxy-8-methylisoquinolino[2,1-b]isoquinolin-7-ium;chloride Chemical compound [Cl-].C1=C(OC)C(OC)=CC2=CC3=C(C=C(C(OC)=C4)OC)C4=CC=[N+]3C(C)=C21 PDYBUYVOPAJLKP-UHFFFAOYSA-M 0.000 description 1
• RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
• VVEPUJCLNRDIEQ-UHFFFAOYSA-N 3,8,9-trimethoxy-5-methylbenzo[c]phenanthridin-5-ium-2-ol;chloride Chemical compound [Cl-].C1=C(OC)C(OC)=CC2=C[N+](C)=C3C(C=C(C(=C4)O)OC)=C4C=CC3=C21 VVEPUJCLNRDIEQ-UHFFFAOYSA-N 0.000 description 1
• LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
• DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
• FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
• 208000009304 Acute Kidney Injury Diseases 0.000 description 1
• 206010001367 Adrenal insufficiency Diseases 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• ZGCSNRKSJLVANE-UHFFFAOYSA-N Aglycone-Rebeccamycin Natural products N1C2=C3NC4=C(Cl)C=CC=C4C3=C(C(=O)NC3=O)C3=C2C2=C1C(Cl)=CC=C2 ZGCSNRKSJLVANE-UHFFFAOYSA-N 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 229930003347 Atropine Natural products 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• 108010045634 B7 Antigens Proteins 0.000 description 1
• 102000005738 B7 Antigens Human genes 0.000 description 1
• OLCWFLWEHWLBTO-HSZRJFAPSA-N BMS-214662 Chemical compound C=1C=CSC=1S(=O)(=O)N([C@@H](C1)CC=2C=CC=CC=2)CC2=CC(C#N)=CC=C2N1CC1=CN=CN1 OLCWFLWEHWLBTO-HSZRJFAPSA-N 0.000 description 1
• 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 229940122361 Bisphosphonate Drugs 0.000 description 1
• 206010005098 Blastomycosis Diseases 0.000 description 1
• 241001674044 Blattodea Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
• 108010063916 CD40 Antigens Proteins 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
• 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 241000321538 Candidia Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 206010057248 Cell death Diseases 0.000 description 1
• 206010008479 Chest Pain Diseases 0.000 description 1
• 241001647378 Chlamydia psittaci Species 0.000 description 1
• 241000606153 Chlamydia trachomatis Species 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 241000223205 Coccidioides immitis Species 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• 206010011376 Crepitations Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 206010011486 Cryptococcal infections Diseases 0.000 description 1
• 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
• 102100033195 DNA ligase 4 Human genes 0.000 description 1
• 239000012626 DNA minor groove binder Substances 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 206010013439 Disseminated cryptococcosis Diseases 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 208000032163 Emerging Communicable disease Diseases 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 241000709661 Enterovirus Species 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
• 206010051841 Exposure to allergen Diseases 0.000 description 1
• 108010014172 Factor V Proteins 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 101800000974 Fibrinopeptide A Proteins 0.000 description 1
• 101800003778 Fibrinopeptide B Proteins 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 206010053759 Growth retardation Diseases 0.000 description 1
• 241000606768 Haemophilus influenzae Species 0.000 description 1
• 208000001204 Hashimoto Disease Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 102000002268 Hexosaminidases Human genes 0.000 description 1
• 108010000540 Hexosaminidases Proteins 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101000721172 Homo sapiens Protein DBF4 homolog A Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
• 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
• 235000003325 Ilex Nutrition 0.000 description 1
• 241000209035 Ilex Species 0.000 description 1
• 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
• 108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 102000003815 Interleukin-11 Human genes 0.000 description 1
• 102100036672 Interleukin-23 receptor Human genes 0.000 description 1
• 101710195550 Interleukin-23 receptor Proteins 0.000 description 1
• 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 102000004890 Interleukin-8 Human genes 0.000 description 1
• 208000037026 Invasive Fungal Infections Diseases 0.000 description 1
• 208000000785 Invasive Pulmonary Aspergillosis Diseases 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• 101150069380 JAK3 gene Proteins 0.000 description 1
• 241000588748 Klebsiella Species 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 108010085895 Laminin Proteins 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 241000947661 Lestis Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 239000000232 Lipid Bilayer Substances 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 240000000233 Melia azedarach Species 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
• ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 description 1
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 241000588621 Moraxella Species 0.000 description 1
• MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
• 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• 241000282339 Mustela Species 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 241000204031 Mycoplasma Species 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 208000006816 Neonatal Sepsis Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 102000005348 Neuraminidase Human genes 0.000 description 1
• 108010006232 Neuraminidase Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 208000001388 Opportunistic Infections Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 241001137886 Ovine respiratory syncytial virus Species 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241000282577 Pan troglodytes Species 0.000 description 1
• 241000711502 Paramyxovirinae Species 0.000 description 1
• 206010034133 Pathogen resistance Diseases 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 229940083963 Peptide antagonist Drugs 0.000 description 1
• 108010013639 Peptidoglycan Proteins 0.000 description 1
• 201000005702 Pertussis Diseases 0.000 description 1
• 201000007100 Pharyngitis Diseases 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
• 206010035734 Pneumonia staphylococcal Diseases 0.000 description 1
• 208000004692 Pneumovirus Infections Diseases 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
• 108010050808 Procollagen Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102100025198 Protein DBF4 homolog A Human genes 0.000 description 1
• 102100027378 Prothrombin Human genes 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
• 208000001431 Psychomotor Agitation Diseases 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 101100478330 Rattus norvegicus Srgn gene Proteins 0.000 description 1
• QEHOIJJIZXRMAN-UHFFFAOYSA-N Rebeccamycin Natural products OC1C(O)C(OC)C(CO)OC1N1C2=C3NC4=C(Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 QEHOIJJIZXRMAN-UHFFFAOYSA-N 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 208000018569 Respiratory Tract disease Diseases 0.000 description 1
• 206010038743 Restlessness Diseases 0.000 description 1
• 201000007981 Reye syndrome Diseases 0.000 description 1
• 206010051497 Rhinotracheitis Diseases 0.000 description 1
• 102000004389 Ribonucleoproteins Human genes 0.000 description 1
• 108010081734 Ribonucleoproteins Proteins 0.000 description 1
• 241000724205 Rice stripe tenuivirus Species 0.000 description 1
• IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
• 241001533467 Rubulavirus Species 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 101100329776 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CUR1 gene Proteins 0.000 description 1
• GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 241000194017 Streptococcus Species 0.000 description 1
• 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• DOLKUORRHHIIJM-UHFFFAOYSA-N TAN-1518 A Natural products COC1(C)C2CC3C(OC(=O)c4ccccc4O)C(=C(C(=O)N)C(=O)C3(O)C(=C2C(=O)c5c(O)c(ccc15)C6CC(O)C(OC(=O)C(=C/C)C)C(C)O6)O)O DOLKUORRHHIIJM-UHFFFAOYSA-N 0.000 description 1
• HVFAJVYSVMYBQY-UHFFFAOYSA-N TAN-1518 B Natural products CCC(=CC)C(=O)OC1C(C)OC(CC1O)c2ccc3c(C(=O)C4=C(O)C5(OC)C(CC4C3(C)OC)C(OC(=O)c6ccccc6O)C(=C(C(=O)N)C5=O)O)c2O HVFAJVYSVMYBQY-UHFFFAOYSA-N 0.000 description 1
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
• 210000000447 Th1 cell Anatomy 0.000 description 1
• 108010000499 Thromboplastin Proteins 0.000 description 1
• 102000002262 Thromboplastin Human genes 0.000 description 1
• 108060008245 Thrombospondin Proteins 0.000 description 1
• 102000002938 Thrombospondin Human genes 0.000 description 1
• DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
• 206010066901 Treatment failure Diseases 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
• 206010045240 Type I hypersensitivity Diseases 0.000 description 1
• 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 206010047513 Vision blurred Diseases 0.000 description 1
• 229930003448 Vitamin K Natural products 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• FHNFHKCVQCLJFQ-NJFSPNSNSA-N Xenon-133 Chemical compound [133Xe] FHNFHKCVQCLJFQ-NJFSPNSNSA-N 0.000 description 1
• SNWJINGOFNDVIF-GIDUJCDVSA-N [3-carbamoyl-4,4a,6,7-tetrahydroxy-8-[4-hydroxy-6-methyl-5-[(E)-2-methylbut-2-enoyl]oxyoxan-2-yl]-11-methoxy-11-methyl-2,5-dioxo-1,11a,12,12a-tetrahydrotetracen-1-yl] 2-hydroxybenzoate Chemical compound O=C1C(C(N)=O)=C(O)C2(O)C(=O)C3=C(O)C4=C(O)C(C5OC(C)C(OC(=O)C(\C)=C\C)C(O)C5)=CC=C4C(OC)(C)C3CC2C1OC(=O)C1=CC=CC=C1O SNWJINGOFNDVIF-GIDUJCDVSA-N 0.000 description 1
• 241000222126 [Candida] glabrata Species 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 108010041979 accutin Proteins 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 208000012871 acute dyspnea Diseases 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 201000011040 acute kidney failure Diseases 0.000 description 1
• 208000012998 acute renal failure Diseases 0.000 description 1
• 238000011374 additional therapy Methods 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
• UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
• 239000000464 adrenergic agent Substances 0.000 description 1
• 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
• 238000011366 aggressive therapy Methods 0.000 description 1
• 239000000809 air pollutant Substances 0.000 description 1
• 231100001243 air pollutant Toxicity 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 229940062527 alendronate Drugs 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000009285 allergic inflammation Effects 0.000 description 1
• 208000030961 allergic reaction Diseases 0.000 description 1
• 210000001132 alveolar macrophage Anatomy 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000002870 angiogenesis inducing agent Substances 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 238000011122 anti-angiogenic therapy Methods 0.000 description 1
• 230000001078 anti-cholinergic effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000009830 antibody antigen interaction Effects 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 239000003430 antimalarial agent Substances 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 238000003782 apoptosis assay Methods 0.000 description 1
• 230000036528 appetite Effects 0.000 description 1
• 235000019789 appetite Nutrition 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 229960000396 atropine Drugs 0.000 description 1
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
• 108010044540 auristatin Proteins 0.000 description 1
• 108010008739 auristatin PHE Proteins 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 229940092705 beclomethasone Drugs 0.000 description 1
• NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229940124748 beta 2 agonist Drugs 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 150000004663 bisphosphonates Chemical class 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
• 229950010231 brequinar Drugs 0.000 description 1
• 230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
• 201000009267 bronchiectasis Diseases 0.000 description 1
• 239000004044 bronchoconstricting agent Substances 0.000 description 1
• 230000007885 bronchoconstriction Effects 0.000 description 1
• 230000003435 bronchoconstrictive effect Effects 0.000 description 1
• 229940124630 bronchodilator Drugs 0.000 description 1
• 239000000168 bronchodilator agent Substances 0.000 description 1
• MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
• 229960005539 bryostatin 1 Drugs 0.000 description 1
• 229960004436 budesonide Drugs 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229940112129 campath Drugs 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 208000032343 candida glabrata infection Diseases 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000002612 cardiopulmonary effect Effects 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000005341 cation exchange Methods 0.000 description 1
• 229960000603 cefalotin Drugs 0.000 description 1
• 229960003012 cefamandole Drugs 0.000 description 1
• OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
• 229960001139 cefazolin Drugs 0.000 description 1
• MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
• 229960001668 cefuroxime Drugs 0.000 description 1
• JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000006041 cell recruitment Effects 0.000 description 1
• 230000010267 cellular communication Effects 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
• HZCWPKGYTCJSEB-UHFFFAOYSA-N chembl118841 Chemical compound C12=CC(OC)=CC=C2NC2=C([N+]([O-])=O)C=CC3=C2C1=NN3CCCN(C)C HZCWPKGYTCJSEB-UHFFFAOYSA-N 0.000 description 1
• SMNPLAKEGAEPJD-UHFFFAOYSA-N chembl34922 Chemical compound Cl.Cl.Cl.C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C=C4N=C(NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 SMNPLAKEGAEPJD-UHFFFAOYSA-N 0.000 description 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 239000000812 cholinergic antagonist Substances 0.000 description 1
• 238000011210 chromatographic step Methods 0.000 description 1
• 201000009950 chronic meningitis Diseases 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 238000002983 circular dichroism Methods 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000005352 clarification Methods 0.000 description 1
• 229960002227 clindamycin Drugs 0.000 description 1
• KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
• ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
• 229960002286 clodronic acid Drugs 0.000 description 1
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
• 201000003486 coccidioidomycosis Diseases 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 208000028831 congenital heart disease Diseases 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 229960000265 cromoglicic acid Drugs 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• 231100000409 cytocidal Toxicity 0.000 description 1
• 230000000445 cytocidal effect Effects 0.000 description 1
• 238000012303 cytoplasmic staining Methods 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 229960000860 dapsone Drugs 0.000 description 1
• 230000002498 deadly effect Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 206010013781 dry mouth Diseases 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• FPJQGFLUORYYPE-UHFFFAOYSA-N epiberberine Chemical compound C1=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C2OCOC2=C1 FPJQGFLUORYYPE-UHFFFAOYSA-N 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 230000000925 erythroid effect Effects 0.000 description 1
• 229960003276 erythromycin Drugs 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 229960000285 ethambutol Drugs 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 229940009626 etidronate Drugs 0.000 description 1
• 229960005293 etodolac Drugs 0.000 description 1
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 210000000416 exudates and transudate Anatomy 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 229960001419 fenoprofen Drugs 0.000 description 1
• 229960001022 fenoterol Drugs 0.000 description 1
• 210000000943 fetal thymocyte Anatomy 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 108010073651 fibrinmonomer Proteins 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 244000144992 flock Species 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 229960005304 fludarabine phosphate Drugs 0.000 description 1
• 229960000676 flunisolide Drugs 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 229960002390 flurbiprofen Drugs 0.000 description 1
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
• 229960002714 fluticasone Drugs 0.000 description 1
• MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
• 229960003765 fluvastatin Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 229960002848 formoterol Drugs 0.000 description 1
• BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
• 239000003517 fume Substances 0.000 description 1
• 229910052733 gallium Inorganic materials 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 229960002706 gusperimus Drugs 0.000 description 1
• 229940047650 haemophilus influenzae Drugs 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• 230000003118 histopathologic effect Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 230000003463 hyperproliferative effect Effects 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 229940015872 ibandronate Drugs 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 229940124622 immune-modulator drug Drugs 0.000 description 1
• 238000003365 immunocytochemistry Methods 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 229940031551 inactivated vaccine Drugs 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 206010021654 increased appetite Diseases 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 229940076144 interleukin-10 Drugs 0.000 description 1
• 229940117681 interleukin-12 Drugs 0.000 description 1
• 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
• 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
• 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
• 229940124829 interleukin-23 Drugs 0.000 description 1
• 229940076264 interleukin-3 Drugs 0.000 description 1
• 108040006856 interleukin-3 receptor activity proteins Proteins 0.000 description 1
• 229940100602 interleukin-5 Drugs 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 208000036732 invasive candidiasis Diseases 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229960001361 ipratropium bromide Drugs 0.000 description 1
• KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 229960003350 isoniazid Drugs 0.000 description 1
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
• 229940039009 isoproterenol Drugs 0.000 description 1
• QRWUHWVLCGLLOK-UHFFFAOYSA-N ist 622 Chemical compound C=1C2=C(C=3C4=5)OC(=O)C4=C(C)C=CC=5OC(=O)C=3C(OC(=O)CCOCC)=C2C=CC=1OC1OC(C)C2OC(C=3C=CC=CC=3)OC2C1OC1OC(C)C(O)C(OC)C1O QRWUHWVLCGLLOK-UHFFFAOYSA-N 0.000 description 1
• 210000001503 joint Anatomy 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 230000021633 leukocyte mediated immunity Effects 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 230000007257 malfunction Effects 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• 210000003071 memory t lymphocyte Anatomy 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 230000003458 metachromatic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 229960002329 methacholine Drugs 0.000 description 1
• NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 229960004023 minocycline Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 229950000844 mizoribine Drugs 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
• 210000004898 n-terminal fragment Anatomy 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
• 229960000515 nafcillin Drugs 0.000 description 1
• 238000001728 nano-filtration Methods 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 229960004398 nedocromil Drugs 0.000 description 1
• RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
• 229950010733 neridronic acid Drugs 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 125000005245 nitryl group Chemical group [N+](=O)([O-])* 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 230000014207 opsonization Effects 0.000 description 1
• 229960002657 orciprenaline Drugs 0.000 description 1
• 230000004768 organ dysfunction Effects 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 150000002902 organometallic compounds Chemical class 0.000 description 1
• 210000003300 oropharynx Anatomy 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
• 229960001019 oxacillin Drugs 0.000 description 1
• 229960002739 oxaprozin Drugs 0.000 description 1
• OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229960001609 oxitropium bromide Drugs 0.000 description 1
• LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
• 229940046231 pamidronate Drugs 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000003950 pathogenic mechanism Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 238000001050 pharmacotherapy Methods 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
• 229960005414 pirbuterol Drugs 0.000 description 1
• 229960002702 piroxicam Drugs 0.000 description 1
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
• 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000004800 polyvinyl chloride Substances 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 230000001144 postural effect Effects 0.000 description 1
• 244000144977 poultry Species 0.000 description 1
• 235000013594 poultry meat Nutrition 0.000 description 1
• 229960004583 pranlukast Drugs 0.000 description 1
• UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• TUZYXOIXSAXUGO-PZAWKZKUSA-M pravastatin(1-) Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-M 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 238000011809 primate model Methods 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000009696 proliferative response Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 229940039716 prothrombin Drugs 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
• 239000012857 radioactive material Substances 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 230000036647 reaction Effects 0.000 description 1
• 229960005567 rebeccamycin Drugs 0.000 description 1
• INSACQSBHKIWNS-QZQSLCQPSA-N rebeccamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 208000004124 rheumatic heart disease Diseases 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 229940049413 rifampicin and isoniazid Drugs 0.000 description 1
• 229940089617 risedronate Drugs 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
• 229950009213 rubitecan Drugs 0.000 description 1
• 229960004017 salmeterol Drugs 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 231100000748 severe hepatic injury Toxicity 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 201000009890 sinusitis Diseases 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 238000010532 solid phase synthesis reaction Methods 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 208000004048 staphylococcal pneumonia Diseases 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 208000022218 streptococcal pneumonia Diseases 0.000 description 1
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
• 229960001940 sulfasalazine Drugs 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 229960000894 sulindac Drugs 0.000 description 1
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
• 230000003319 supportive effect Effects 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 208000008203 tachypnea Diseases 0.000 description 1
• 206010043089 tachypnoea Diseases 0.000 description 1
• 229950008418 talipexole Drugs 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229910052713 technetium Inorganic materials 0.000 description 1
• GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• 229910052716 thallium Inorganic materials 0.000 description 1
• BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 229940019375 tiludronate Drugs 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 208000037816 tissue injury Diseases 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• 229960001017 tolmetin Drugs 0.000 description 1
• UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 229960001005 tuberculin Drugs 0.000 description 1
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
• KKGVHKUKFAVMNN-UHFFFAOYSA-N uce-1022 Chemical compound C1=C(O)C=C2C=C(C(=O)C=3C(=C(O)C=C(C=3)O)C3=O)C3=C(O)C2=C1OS(O)(=O)=O KKGVHKUKFAVMNN-UHFFFAOYSA-N 0.000 description 1
• YNAKLZFMOFNLRE-UHFFFAOYSA-N uce-6 Chemical compound O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1C=C1C=C(O)C=C(CC(=O)CC(O)C)C1=C2O YNAKLZFMOFNLRE-UHFFFAOYSA-N 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 210000002229 urogenital system Anatomy 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 239000013598 vector Substances 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 235000019168 vitamin K Nutrition 0.000 description 1
• 239000011712 vitamin K Substances 0.000 description 1
• 150000003721 vitamin K derivatives Chemical class 0.000 description 1
• 229940046010 vitamin k Drugs 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1
• 229950004094 xenon (133xe) Drugs 0.000 description 1
• 229960005332 zileuton Drugs 0.000 description 1
• MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1